• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Coherus BioSciences, Inc. - Common Stock (NQ:CHRS)

    0.7793 +0.0232 (+3.07%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Coherus BioSciences, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
    – First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor – 
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Top movers in Friday's after hours session
    As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
    Via Chartmill
    Which stocks are moving before the opening bell on Tuesday?
    Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. 
    Via Chartmill
    Earnings Scheduled For May 12, 2025
    Via Benzinga
    Earnings Preview: Coherus BioSciences
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus to Participate in Upcoming Investor Conferences
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Which stocks are moving after the closing bell on Wednesday?
    Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
    Via Chartmill
    Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 10, 2025
    Via Benzinga
    Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
    Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC. 
    Via Benzinga
    Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024
    CHRS stock results show that Coherus BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.